TY - JOUR
T1 - ASO Author Reflections
T2 - Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Undergoing Neoadjuvant Therapy
AU - Jacover, Arielle
AU - Pencovich, Niv
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025
Y1 - 2025
N2 - Borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) presents a therapeutic challenge, balancing the benefits of neoadjuvant therapy (NT) against the risk of missing the opportunity for cure by upfront surgery. In this retrospective study, we evaluated real-world outcomes in patients with BR-PDAC undergoing NT and identified elevated baseline carcinoembryonic antigen (CEA) as an independent predictor of failure to reach surgery, primarily due to local tumor progression. Our findings suggest that CEA may serve as a practical biomarker to guide treatment selection between NT and upfront surgery.
AB - Borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) presents a therapeutic challenge, balancing the benefits of neoadjuvant therapy (NT) against the risk of missing the opportunity for cure by upfront surgery. In this retrospective study, we evaluated real-world outcomes in patients with BR-PDAC undergoing NT and identified elevated baseline carcinoembryonic antigen (CEA) as an independent predictor of failure to reach surgery, primarily due to local tumor progression. Our findings suggest that CEA may serve as a practical biomarker to guide treatment selection between NT and upfront surgery.
UR - http://www.scopus.com/inward/record.url?scp=105007108894&partnerID=8YFLogxK
U2 - 10.1245/s10434-025-17536-x
DO - 10.1245/s10434-025-17536-x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 40437339
AN - SCOPUS:105007108894
SN - 1068-9265
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
ER -
